GBA Presents: House of Gummy-!

stonedinvestor said:
Ripe & Fresh
IBD points out Cantaloupe.

The 5% buy zone from just above 6.22 goes up to 6.53. So, CTLP shares quickly rose out of the ideal buy zone and have gotten extended.

Plus, Cantaloupe has now reached the 20%-25% profit zone, a good time to take at least partial gains.

Recently, the stock not only took back all of its declines in May. It also kept the new breakout intact. On June 1 and 2, the stock advanced in above-average volume, a sign of unusually healthy demand.

Plus, the 10% gain in the week ended June 9 came in accelerating weekly turnover. That's another telltale sign of healthy and strengthening demand among institutional investors.

Cantaloupe made the IBD Stock Screener as one among 136 stocks with a top Composite Rating and trading under $10 a share. That rating has stayed stable for days at 89 but has now edged up to a sterling 91. The 96 Relative Strength Rating is rising again and healthy.

The stock's relative strength line powered into new high ground last month — a classic sign that CTLP is sharply outperforming the S&P 500. The RS line has since cooled off a bit.

Cantaloupe does not sell fruit. The Malvern, Pa., firm provides both hardware and software for the self-service business market. Its Three Square Market product is a "one stop shop for everything micro markets." Cantaloupe's Seed Live software helps users track and analyze sales information in real time.

Shares roared after Cantaloupe reported a 200% spike in fiscal second-quarter earnings to 9 cents a share. Sales rose 20% to $60.4 million. The firm lost a cumulative 16 cents a share in the prior three quarters. However, Wall Street sees Cantaloupe posting earnings of 7 cents a share in the fiscal year ending in June.

CTLP's market value has surpassed $550 million. The small cap holds 72.5 million shares outstanding and a float of 57.2 million freely traded shares.


SOUNDS YUMMY-!
More...




THIS IS MY ONLY STOCK ON PATHETIC WATCH LIST!!! HELP!!!!!!!!!!!

Cantaloupe, Inc. (CTLP)
NasdaqGS - NasdaqGS Real Time Price.

7.96+0.09 (+1.14%)
At close: June 30 04:00PM EDT
8.25 +0.29 (+3.64%)
 
Van-> Great Spot!

Extreme Networks, Inc. (EXTR)
NasdaqGS - NasdaqGS Real Time Price.
17.86+1.30(+7.85%)<-----------------:thumbsup:
At close: October 28



UPDATE- $25 basically at a 52 week high// is this the first tech stk to regain it's high?
 
Lot of chatter at the HF about this-- not clued in-


Fidelity National Information Services, Inc. (FIS)
NYSE - Nasdaq Real Time Price.

57.42+2.72 (+4.97%)
As of 09:32AM EDT. Market open.
 
Fidelity National Information Stock Gains on Report of Private-Equity Interest in Worldpay





Updated July 3, 2023 8:54 am ET / Original July 3, 2023 8:13 am ET


im-60609

Fidelity National said in February it planned to spin off Worldpay.
Fidelity National Information Services’ shares raced higher early Monday after a report cited two private-equity groups as potential buyers for its payments provider business Worldpay Group.

Worldpay Group, acquired by Fidelity National FIS +5.36% (ticker: FIS) in 2019, is being valued at more than $15 billion, a Financial Times report said on Friday, citing five people familiar with the matter. Advent International and GTCR are the two private-equity groups weighing bids for a majority stake in the payments company, while large Wall Street banks have discussed providing funding, the report said.


Fidelity National stock moved 9% higher to trade at $59.59 in premarket trading on Monday.

The company, Advent, and GTCR didn’t immediately respond to requests for comment from Barron’s. Fidelity Nationaldeclined to comment to the Financial Times. It said in February it planned to spin off Worldpay.
 
Wait for 10:30 retrace on gummies<-----

b0d491a839e87086e5d5b9654a881c16


Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) announced topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis (PBC) who have shown inadequate response or intolerance to ursodeoxycholic acid (UDCA), the current standard therapy.

PBC is a chronic disease in which the bile ducts in the liver are slowly destroyed.

The trial met its primary composite endpoint, with 51% of patients on elafibranor 80mg exhibiting a cholestasis response compared to 4% on placebo.

Cholestasis occurs when the flow of bile from the liver is reduced or blocked. Bile is fluid produced by the liver that aids in the digestion of food, especially fats.
 
vanzandt said:
Yeah I think he said he was leaving early today. I called Suffolk County and made sure they doubled up on lifeguards this weekend; and saved an extra bed in the drunk-tank.

Know what home builder never gets any attention and I had forgot about? Howard Hughes Corp. HHC.

I owned it for awhile back in the day (I think I lost $5/share if recall :rolleyes: ), and since all these builders are on fire, I thought I'd pull it up.

This damn thing has barely budged. It's a good company. They build planned communities, multi-family, condo's, all kinds of stuff. I'm gonna dig into why it hasn't moved much, but for now I'm giving it a moderate VZ granny stock upgrade.

HHC----> $78

More to follow on this one.
More...
$79.57
 
You must log in or register to reply here.
Back
Top